Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234256 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C9GAAUSP2 | |
| SCHEMBL12538431 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C9GAAUSP2 | |
| Ethylamine SCHEMBL11493804 | 0.88 | CYP17A1 (0.43) | ALDH1A1TSHRCYP2C9GAAUSP2 | |
| SCHEMBL12808430 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TSHRGAAHPGDNPSR1 | |
| SCHEMBL598140 | 0.87 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP2C9GAAUSP2 | |
| SCHEMBL17149581 | 0.82 | TRPA1 (0.42) | ALDH1A1AOC3IDO1TDO2 | |
| Hydrogen Peroxide SCHEMBL11434421 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP2C9GAAUSP2 | |
| SCHEMBL21503575 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDAOC3IDO1TDO2 | |
| SCHEMBL18286641 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDAOC3IDO1TDO2 | |
| SCHEMBL782013 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDAOC3IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700232-B2 | Comprises an electrolyte salt in a non-aqueous solvent which contains a tert-alkylbenzene compound of high purity; battery improved in safety, excellent in cycle performance and storage performance at a high temperature, improved safety | UBE INDUSTRIES, LTD. (JP) | 2010-04-20 | — | — | US | claimed |
| US-20080248399-A1 | Comprises an electrolyte salt in a non-aqueous solvent which contains a tert-alkylbenzene compound of high purity; battery improved in safety, excellent in cycle performance and storage performance at a high temperature, improved safety | UBE INDUSTRIES, LTD. (JP) | 2008-10-09 | — | — | US | claimed |
| CN-1954456-A | Nonaqueous electrolyte solution for lithium secondary battery | UBE INDUSTRIES (JP) | 2007-04-25 | — | — | CN | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| EP-4400504-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-06-08 | — | — | US | disclosed |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2009108766-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER ' S DISEASE | SCHERING CORPORATION (US) | 2009-09-03 | — | — | WO | disclosed |
| CN-101432923-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080248399-A1 | Comprises an electrolyte salt in a non-aqueous solvent which contains a tert-alkylbenzene compound of high purity; battery improved in safety, excellent in cycle performance and storage performance at a high temperature, improved safety | UBE INDUSTRIES, LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | JANSSEN SCIENCES IRELAND UC (IE) | 2008-06-19 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | KDM1B, KDM3A, KDM1A | ALDH1A1 3076/4885TSHR 4390/4885CYP2C9 3689/4885 |
| US-20080146564-A1 | 1,3-Dihydro-Benzimidazol-2-Ylidene Amines as Inhibitors of Respiratory Syncytial Virus Replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, RTF2 | ALDH1A1 1249/4885TSHR 1965/4885CYP2C9 1745/4885 |
| US-20230203003-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | ALDH1A1 2288/4885TSHR 3942/4885CYP2C9 4027/4885 |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | FGFR1, FGFR3, FGFR4 | ALDH1A1 1040/4885TSHR 4216/4885CYP2C9 2995/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | ALDH1A1 3710/4885TSHR 2080/4885CYP2C9 475/4885 |
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | ALDH1A1 4239/4885TSHR 3306/4885CYP2C9 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.